Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T Cell Therapy in Refractory Pemphigus Vulgaris
NCT07681388Recruiting
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous CD19 CAR-T cells in pemphigus vulgaris (PV). Primary endpoints: Incidence and Severity of Treatment-Emergent Adverse Events at Day 90, Change From Baseline in Pemphigus Disease Area Index Score at Week 12 and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
autologous CD19 CAR-T cells
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT07681388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07681388.